I’ve been living in recovery from opioid use disorder for eight and a half years, and this might be a weird thing to say about addiction, but I feel lucky—like I dodged a bullet. I was addicted to opioids in Florida throughout the early 2000s, during the heyday of pill mills that flooded the streets...Read More

The FDA also approved the first generic non-prescription naloxone drug in July 2023. The US Food and Drug Administration (FDA) approved the second over-the-counter (OTC) naloxone nasal spray product, RiVive (3mg) by non-profit pharmaceutical company Harm Reduction Therapeutics, for the emergency treatment of known or suspected opioid overdose. This approval follows the agency’s approval of Emergent...Read More